AngioDynamics, Inc. has reported its financial results for the first quarter of fiscal year 2026, ending on August 31, 2025. The company's net sales for the quarter were $75.7 million, representing a 12.2% increase compared to the prior-year quarter. Med tech net sales saw significant growth, reaching $35.3 million, a 26.1% increase from the prior-year period, and med device net sales increased by 2.3% to $40.4 million.
The company reported a GAAP gross margin of 55.3% and a GAAP loss per share of $0.26. Adjusted EBITDA for the quarter was $2.2 million, a notable improvement compared to the prior year's ($0.2) million.
The company ended the quarter with $38.8 million in cash and cash equivalents and expects to be cash flow positive for the full fiscal year 2026. It also raised its full-year net sales guidance, med tech net sales growth, adjusted EBITDA, and adjusted EPS for fiscal year 2026.
AngioDynamics' President and CEO, Jim Clemmer, highlighted the company's continued momentum in fiscal 2026 and emphasized its sustained profitable growth driven by operational excellence.
The company's med tech segment delivered its fourth consecutive quarter of over 20% revenue growth. Auryon sales increased by 20.1%, mechanical thrombectomy business sales increased by 41.2%, and nanoknife sales increased by 26.7%, including 31.3% growth in probes.
The company's gross margin for the first quarter of fiscal 2026 was 55.3%, a 90 basis points increase compared to the prior year. Additionally, adjusted EBITDA for the first quarter of fiscal 2026 was $2.2 million, a significant improvement from the ($0.2) million reported in the first quarter of fiscal 2025.
AngioDynamics also achieved significant clinical milestones, enrolling the first patient in both the ambition BTK trial and the Recover-AV clinical trial. Furthermore, the Nanoknife Preserve study results were published in a leading European journal, demonstrating the effectiveness of irreversible electroporation with the Nanoknife system in treating prostate cancer.
The company raised its fiscal year 2026 guidance for various metrics, including net sales, med tech net sales growth, adjusted EBITDA, and adjusted EPS, reflecting its confidence in continued growth and value creation.
AngioDynamics continues to expect a $4.0 * $6.0 million impact from tariffs for the full fiscal year 2026, and it encourages investors to consider non-GAAP measures alongside GAAP measures to analyze the company's performance over time. Following these announcements, the company's shares moved 7.68%, and are now trading at a price of $11.9202. If you want to know more, read the company's complete 8-K report here.
